A compound for the manufacturing of a medicament for reducing or preventing mesothelial cell damage includes a mixture of a carrier gas and between 1 volume percent and 29 volume percent of nitrous oxide gas (N2O) and can be used for prevention of adhesion formation, pain reduction, reducing or preventing acute inflammation, reducing or preventing CO2 resorbtion or reducing tumor cell implantation upon surgery.
